Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2657)	1/12/2010 10:09:20 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MAPP had a good UG yesterday.<g> bigcharts.marketwatch.com It announced that the FDA had informed it that another PIII is not required for the LEVADEX NDA for the treatment of migraine.<g> MAPP announced last May that the PIII FREEDOM-301 of LEVADEX met all four primary endpoints. The main resistance is the May 28 H at $13.25 and suppoprt at $10.60 if it closes yesterday;s UG as expected.<g> MAPP has closed its Feb27 DG, but didn't close its May 27 UG.<g> bigcharts.marketwatch.com MAPP has been cutting its losses in the last 3Qs and the EL for 2009 is around $0.27 vs. $3.58 in 2008. But for 2010 another loss around $1.90 is expected. In Novemeber it said it has secured commitment for up to $60M in financing.<g> MAPP has a good institutional following. Will see if it can hold at the important looking support around the $8 level.<g> bigcharts.marketwatch.com Bernard